
Based on the zzso evidence of zzso I zzso zzso by zzso zzso and decreased zzso zzso by zzso we evaluated combinations of zzso and zzso in patients with advanced solid zzso 

Initially, patients received zzso on day 1 and zzso on days 2, 8, 15 and 22, every 6 zzso zzso dose was fixed at 6 zzso and cumulative doses of zzso zzso were not zzso zzso was escalated in 25 zzso zzso Due to zzso zzso the schedule was subsequently shortened to 4 weeks, omitting zzso on days 15 and zzso In the second part of the study, zzso 400 zzso orally twice daily was added to zzso zzso Potential zzso interactions and zzso and zzso zzso gene expressions in zzso cells were zzso 

zzso patients were zzso zzso 125 zzso on days 2 and 8 in combination with zzso 6 zzso on day 1 every 4 weeks is recommended for future zzso zzso and zzso are zzso The addition of zzso resulted in unacceptable zzso despite reductions on zzso zzso No relevant zzso interactions occurred between zzso and zzso and mean increases in zzso were zzso Sixteen of 36 patients zzso for zzso had zzso zzso activity, including 1 complete, 4 zzso 10 minor and 1 tumor marker zzso Four patients had prolonged zzso zzso zzso zzso disease, not included in zzso or zzso Patients experiencing complete and partial responses had higher increments in zzso zzso 

zzso of zzso by zzso is zzso devoid of pharmacological interactions and active in solid zzso The lack of improvement in therapeutic index does not support the addition of zzso 

